Burning Rock Biotech Ltd (BNR)
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
- Ticker
- BNR
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- 52-week range
- $6.79 - $41.72
Valuation
- Share price
- $13.07 (close of Nov 18, 2026)
- P/E (TTM)
- -15.27x
- Price to book
- 1.78x
- Price to free cash flow
- -27.17x
Price performance
| Period | Change |
|---|---|
| 1 day | +4.56% |
| 5 days | -1.28% |
| 1 month | +1.32% |
| 3 months | +40.39% |
| 6 months | -21.74% |
| Year to date | -35.14% |
| 1 year | -8.67% |
| 3 years | +45.22% |
| 5 years | -91.84% |
| All time | -94.69% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 0.48%
- Shares short
- 34.33K
- Days to cover
- 1.34
- Change since prior report
- -6.95%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -10.34%
- Return on invested capital
- -9.48%
- Return on assets
- -6.75%
- Return on capital employed
- -9.56%
- Gross margin
- 74.67%
- Net margin
- -10.26%
- EBITDA margin
- -6.13%
- Revenue growth
- 4.60%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -3.68%
- Current ratio
- 3.05x
- Net debt to EBITDA
- 13.60x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Shares outstanding
- 10.79M
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 74.67% | -10.26% | -10.34% | -9.48% |
| 2024-12-31 | 70.26% | -67.20% | -59.68% | -56.47% |
| 2023-12-31 | 67.59% | -121.63% | -85.07% | -85.73% |
| 2022-12-31 | 67.47% | -172.44% | -83.85% | -81.08% |
| 2021-12-31 | 71.70% | -156.87% | -43.17% | -41.26% |
| 2020-12-31 | 73.02% | -94.73% | -16.82% | -16.98% |
| 2019-12-31 | 71.61% | -44.32% | - | - |
| 2018-12-31 | 64.66% | -84.98% | - | - |
| 2017-12-31 | 64.49% | -118.09% | -77.91% | - |
Investor relations
Next earnings report
- Next confirmed report
- Nov 19, 2026
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-09-10 | Jun 2026 | - |
| 2026-06-09 | Mar 2026 | - |
| 2026-03-12 | Dec 2025 | - |
| 2025-11-20 | Sep 2025 | - |
| 2025-09-08 | Jun 2025 | - |
| 2025-06-06 | Mar 2025 | - |
| 2025-03-25 | Dec 2024 | - |
| 2024-12-03 | Sep 2024 | - |
Filings and sources
- Company website
- brbiotech.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV) · IDEXX Laboratories Inc (IDXX) · Waters Corp (WAT) · Illumina, Inc. (ILMN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades